Hints and tips:
Related Special Reports
...This article has been amended to clarify details of the proposed drug trial by the NHS and Novartis...
...Merck, BMS, J&J, Novartis and some trade groups have launched a legal broadside against them, filing lawsuits in several different courts across the US....
...Haleon was a joint venture between GSK and Pfizer that included consumer brands acquired from Novartis....
...In 2020, when pharmaceutical manufacturers Roche and Novartis were fined €444mn for allegedly pushing their jointly marketed eye medicine Lucentis over a cheaper alternative, Thill-Tayara successfully argued...
...Psilocybin was first clinically manufactured in 1959 by Sandoz, now part of Novartis, but the company had never commercialised it....
...Novartis said it did not think the decline in sales was linked to reports of deaths of two children who had taken the drug....
...At Swiss pharmaceutical company Novartis, suppliers — which range from producers of ingredients, materials and finished goods to transport and real estate businesses — generate just over 90 per cent of its...
...In the canton of Basel-Stadt for example, home to 201,000 residents as well as the pharmaceutical companies Roche and Novartis, 20 per cent of government revenues — about CHF600m annually — come from corporation...
...A Parkinson’s drug, licensed to US company Sio in 2018, has underlined the potential of this dual approach....
...When Shannon Thyme Klinger left the top legal job at Swiss pharmaceutical group Novartis to join US biotech Moderna this month, she was motivated by a deep sense of purpose — professional and personal....
...Novartis, Roche, Pfizer and Biogen have spent billions on similar deals. It can have a big impact on previously untreatable diseases....
...AskBio, which has more than 500 patents, is also trying to develop therapies for more common illnesses such as Parkinson’s disease and heart failure....
...The deal settles civil allegations against its US arm, Novartis Pharmaceuticals Corporation, and is the company’s third big resolution with US authorities in recent months....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...“The view that Zolgensma is the most expensive therapy in the world is, frankly, wrong,” says David Lennon, president of AveXis, the biotech acquired by Novartis that developed it....
...The Big Three are on course to control 40 per cent of the votes in American corporations in a couple of decades....
...Large, venerable corporations can struggle to see what lies ahead for their industry. Consider Novartis....
...Novartis will use the technology to treat cancer and Sanofi to treat haemophilia....
...The pharmaceuticals industry was a big beneficiary of the president's recent tax changes. Here’s our guide to drug pricing....
...The lawsuit is a stark example of the use of non-competes by large corporations, even against low-level hourly wage workers....
...As the pace of discoveries has quickened in recent years, it has turned into a kind of rock festival for the pharmaceutical industry....
...The company had just completed its first big live demonstration for a pharmaceutical company....
...Earlier projects focus on conditions such as Parkinson’s, Huntington’s disease, cystic fibrosis and ultra rare “orphan” illnesses....
...China's regulator has approved 60,000 TCM medicines — almost a third of the country's pharmaceuticals market, the world's second largest....
...Novartis, the Swiss pharmaceuticals group, will also be a strategic investor in the vehicle, and both it and Verily will appoint two members each to the fund’s scientific advisory board....
International Edition